How much cash does Praxis Precision Medicines, Inc. generate?

Praxis Precision Medicines, Inc. (PRAX) generated -$282.2M in operating cash flow over the trailing twelve months.

What is Praxis Precision Medicines, Inc.'s free cash flow?

After $118.0K of capital expenditures, Praxis Precision Medicines, Inc.'s free cash flow was -$282.3M over the trailing twelve months, down 72.3% year over year.

Where does Praxis Precision Medicines, Inc.'s cash flow data come from?

Every line is extracted from Praxis Precision Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Praxis Precision Medicines, Inc. PRAX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$326.53M-53.6%	-$303.27M-65.9%	-$273.04M-80.8%	-$251.01M-103%	-$212.56M-69.5%
Depreciation and amortization	$132K-54.9%	$140K-60.9%	$159K-62.3%	$232K-47.2%	$293K-33.1%
Stock-based compensation	$42.27M+18.5%	$33.94M-17.9%	$32.58M-15.4%	$37.56M+18.0%	$35.67M+12.4%
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	——	——	——	——	$8.44M—
Change in other assets	——	——	——	$51K—	$780K—
Other working capital changes	$2K0.0%	$0-100%	-$11K—	$2K+167%	$2K+200%
Non-cash operating lease expense	$988K+3.1%	$1.04M+11.5%	$1.01M+11.5%	$985K+11.4%	$958K+11.4%
Change in operating lease liabilities	——	——	——	——	-$1.15M-10.8%
Net cash from operating activities	-$282.21M-72.2%	-$249.07M-89.0%	-$228.87M-130%	-$191.31M-101%	-$163.91M-65.3%
Capital expenditures	——	——	——	$56K+12.0%	$0-100%
Purchases of investments	$993.54M+150%	$623.81M+67.9%	$302.96M+0.3%	$239.78M-17.4%	$397.36M+336%
Net cash from investing activities	-$622.25M—	-$329.04M—	-$11.57M—	——	——
Proceeds from issuance of common stock	$13.83M+354%	$13.27M+404%	$3.64M+375%	$3.03M+436%	$3.05M+566%
Taxes paid for net share settlement	$13.82M+911%	$2.09M+578%	$1.43M+815%	$1.38M+782%	$1.37M+829%
Net cash from financing activities	$1.26B+226%	$702.17M+36.5%	$203.42M-49.7%	$198.1M-50.9%	$385.84M+50.4%
Net increase (decrease) in cash	$370.77M+1,715%	$141.96M+0.7%	-$19.12M—	$12.27M—	$20.42M—
Accretion (Amortization) of Discounts and Premiums, Investments	$3.02M-51.0%	$3.59M-28.3%	$4.31M—	$5.61M—	$6.16M—
Depreciation	$132K-54.9%	$140K-60.9%	$159K-62.3%	$232K-47.2%	$293K-33.1%
Operating lease liabilities	——	——	——	——	-$1.15M-10.8%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	$51K—	$780K—
Operating lease right-of-use asset amortization	$988K+3.1%	$1.04M+11.5%	$1.01M+11.5%	$985K+11.4%	$958K+11.4%
Other Noncash Income (Expense)	——	$7K—	$5.25K—	$3.5K—	$1.75K—
Accrued payables for capital expenditures	——	——	——	——	——
Increase Decrease In Operating Lease Liability	——	——	——	——	-$1.15M-10.8%
Removal of right-of-use assets in connection with lease termination	——	——	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	——
Free cash flow	-$282.33M-72.2%	-$249.12M-89.1%	-$228.92M-130%	-$191.36M-101%	-$163.91M-65.2%
Free cash flow	-$282.33M-72.2%	-$249.12M-89.1%	-$228.92M-130%	-$191.36M-101%	-$163.91M-65.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Praxis Precision Medicines, Inc. generate?: Praxis Precision Medicines, Inc. (PRAX) generated -$282.2M in operating cash flow over the trailing twelve months.
What is Praxis Precision Medicines, Inc.'s free cash flow?: After $118.0K of capital expenditures, Praxis Precision Medicines, Inc.'s free cash flow was -$282.3M over the trailing twelve months, down 72.3% year over year.
Where does Praxis Precision Medicines, Inc.'s cash flow data come from?: Every line is extracted from Praxis Precision Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.